Published in Antimicrob Agents Chemother on October 01, 2001
Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res (2005) 1.58
Burkholderia is highly resistant to human Beta-defensin 3. Antimicrob Agents Chemother (2003) 1.29
Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? Int J Antimicrob Agents (2011) 1.28
Phenylbutyrate induces antimicrobial peptide expression. Antimicrob Agents Chemother (2009) 1.21
Cathelicidin-related antimicrobial peptide is required for effective lung mucosal immunity in Gram-negative bacterial pneumonia. J Immunol (2012) 1.20
Host defense peptides in the oral cavity and the lung: similarities and differences. J Dent Res (2008) 1.19
Susceptibility of Pseudomonas aeruginosa Biofilm to Alpha-Helical Peptides: D-enantiomer of LL-37. Front Microbiol (2011) 1.14
Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. Antimicrob Agents Chemother (2002) 1.11
Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology (2005) 1.07
Influenza virus A M2 protein generates negative Gaussian membrane curvature necessary for budding and scission. J Am Chem Soc (2013) 1.04
7-O-malonyl macrolactin A, a new macrolactin antibiotic from Bacillus subtilis active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and a small-colony variant of Burkholderia cepacia. Antimicrob Agents Chemother (2006) 1.04
Enhancement of antimicrobial activity against pseudomonas aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob Agents Chemother (2006) 1.03
In vitro antimicrobial activity of natural toxins and animal venoms tested against Burkholderia pseudomallei. BMC Infect Dis (2006) 0.99
The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds. Front Immunol (2013) 0.97
Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. BMC Microbiol (2012) 0.92
Antimicrobial peptides and induced membrane curvature: geometry, coordination chemistry, and molecular engineering. Curr Opin Solid State Mater Sci (2013) 0.89
High-yield expression of isotopically labeled peptides for use in NMR studies. Protein Sci (2003) 0.88
Novispirin G10-induced lung toxicity in a Klebsiella pneumoniae infection model. Antimicrob Agents Chemother (2003) 0.83
Immunostimulation in the era of the metagenome. Cell Mol Immunol (2011) 0.79
Linocin and OmpW Are Involved in Attachment of the Cystic Fibrosis-Associated Pathogen Burkholderia cepacia Complex to Lung Epithelial Cells and Protect Mice against Infection. Infect Immun (2016) 0.79
Green fluorescent protein as a scaffold for high efficiency production of functional bacteriotoxic proteins in Escherichia coli. Sci Rep (2016) 0.75
Antibiofilm agents: A new perspective for antimicrobial strategy. J Microbiol (2017) 0.75
What can machine learning do for antimicrobial peptides, and what can antimicrobial peptides do for machine learning? Interface Focus (2017) 0.75
D-BMAP18 Antimicrobial Peptide Is Active In vitro, Resists to Pulmonary Proteases but Loses Its Activity in a Murine Model of Pseudomonas aeruginosa Lung Infection. Front Chem (2017) 0.75
Bacterial biofilms: a common cause of persistent infections. Science (1999) 40.82
Microbial biofilms. Annu Rev Microbiol (1995) 21.58
Chromosomal genetics of Pseudomonas. Microbiol Rev (1979) 13.65
Peptide antibiotics. Lancet (1997) 6.76
The changing epidemiology of cystic fibrosis. J Pediatr (1993) 5.50
Cationic peptides: a new source of antibiotics. Trends Biotechnol (1998) 5.10
Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis (1998) 4.82
Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science (1999) 3.98
Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med (1993) 3.27
Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett (1995) 3.21
Development of rRNA-based PCR assays for identification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients. J Clin Microbiol (1999) 3.19
FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci U S A (1995) 2.89
Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun (1995) 2.87
Differentiated structure and function of cultures from human tracheal epithelium. Am J Physiol (1992) 2.68
Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem (1997) 2.38
Concurrent assessment of inner and outer membrane permeabilization and bacteriolysis in E. coli by multiple-wavelength spectrophotometry. J Immunol Methods (1988) 2.31
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr (1990) 2.28
Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun (2000) 2.24
Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis (1996) 2.23
Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun (1996) 2.13
Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol (1995) 2.11
Adenovirus-mediated gene transfer to ciliated airway epithelia requires prolonged incubation time. J Virol (1996) 1.98
Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr (1998) 1.97
Cystic fibrosis. Lancet (1998) 1.66
SMAP-29: a potent antibacterial and antifungal peptide from sheep leukocytes. FEBS Lett (1999) 1.51
Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol (1999) 1.51
Influence of proline residues on the antibacterial and synergistic activities of alpha-helical peptides. Biochemistry (1999) 1.48
Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center. Eur J Clin Microbiol Infect Dis (1996) 1.31
Complementary DNA sequence of rabbit CAP18--a unique lipopolysaccharide binding protein. Biochem Biophys Res Commun (1991) 1.30
Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol (1998) 1.26
cDNA sequences of three sheep myeloid cathelicidins. FEBS Lett (1995) 1.20
Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother (1995) 1.19
Molecular analysis of the sheep cathelin family reveals a novel antimicrobial peptide. FEBS Lett (1995) 1.19
Localization and genomic organization of sheep antimicrobial peptide genes. Gene (1998) 1.13
Use of aerosolized antibiotics in patients with cystic fibrosis. Chest (1999) 0.92
A novel murine cathelin-like protein expressed in bone marrow. FEBS Lett (1996) 0.86
Large scale isolation of functionally active components of the human complement system. J Biol Chem (1981) 5.26
Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A (1998) 3.85
Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest (1998) 3.78
Tritium labeling of proteins to high specific radioactivity by reduction methylation. J Biol Chem (1980) 3.04
Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci U S A (1980) 3.00
Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis (1999) 2.61
Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol (2000) 2.55
Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. J Biol Chem (2001) 2.50
A mouse model for the delta F508 allele of cystic fibrosis. J Clin Invest (1995) 2.48
The cDNA sequence for the protein-tyrosine kinase substrate p36 (calpactin I heavy chain) reveals a multidomain protein with internal repeats. Cell (1986) 2.36
Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun (2000) 2.24
Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun (1999) 2.19
DNA sequence analysis of regions surrounding blaCMY-2 from multiple Salmonella plasmid backbones. Antimicrob Agents Chemother (2004) 2.18
Altered fluid transport across airway epithelium in cystic fibrosis. Science (1993) 2.09
Discovery of new human beta-defensins using a genomics-based approach. Gene (2001) 2.08
Cloning, expression, and tissue distribution of a human amiloride-sensitive Na+ channel. Am J Physiol (1994) 2.07
Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest (1998) 2.05
Metabolism of gallic acid and syringic acid by Pseudomonas putida. J Biol Chem (1972) 2.04
Purification and properties of 4-hydroxy-4-methyl-2-oxoglutarate aldolase. J Biol Chem (1972) 2.04
Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia. Hum Gene Ther (1998) 2.00
Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation. Gene (1998) 1.99
Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production. Gene Ther (2005) 1.93
Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol (2001) 1.86
Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes. J Exp Med (1977) 1.79
Amino-terminal sequence of p36 and associated p10: identification of the site of tyrosine phosphorylation and homology with S-100. Proc Natl Acad Sci U S A (1985) 1.72
Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med (1995) 1.70
Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc Natl Acad Sci U S A (1987) 1.68
Third component of human complement: appearance of a sulfhydryl group following chemical or enzymatic inactivation. Biochemistry (1980) 1.67
Characterization of the human complement (c3b) receptor with a fluid phase C3b dimer. J Immunol (1981) 1.55
Disruption of the beta subunit of the epithelial Na+ channel in mice: hyperkalemia and neonatal death associated with a pseudohypoaldosteronism phenotype. Proc Natl Acad Sci U S A (1999) 1.53
Structural analysis of human complement protein H: homology with C4b binding protein, beta 2-glycoprotein I, and the Ba fragment of B2. J Immunol (1986) 1.53
Transient surfactant protein B deficiency in a term infant with severe respiratory failure. J Pediatr (1998) 1.53
Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol (2001) 1.52
Human serum amyloid A (SAA): biosynthesis and postsynthetic processing of preSAA and structural variants defined by complementary DNA. Biochemistry (1985) 1.49
Fifth component of human complement: purification from plasma and polypeptide chain structure. Biochemistry (1979) 1.49
Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997. Diagn Microbiol Infect Dis (1999) 1.46
Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J Clin Invest (1999) 1.46
Influence of cell polarity on retrovirus-mediated gene transfer to differentiated human airway epithelia. J Virol (1998) 1.46
Third component of human complement: structural analysis of the polypeptide chains of C3 and C3b. Biochemistry (1979) 1.44
Integrase-defective lentiviral vectors: progress and applications. Gene Ther (2009) 1.41
Third component of human complement: structural requirements for its function. Biochemistry (1980) 1.38
Murine protein H is comprised of 20 repeating units, 61 amino acids in length. Proc Natl Acad Sci U S A (1986) 1.37
Nucleotide sequence of complementary DNA and derived amino acid sequence of murine complement protein C3. Philos Trans R Soc Lond B Biol Sci (1984) 1.29
Primary structure of bovine calpactin I heavy chain (p36), a major cellular substrate for retroviral protein-tyrosine kinases: homology with the human phospholipase A2 inhibitor lipocortin. Biochemistry (1986) 1.28
Orientation and dynamics of an antimicrobial peptide in the lipid bilayer by solid-state NMR spectroscopy. Biophys J (2001) 1.27
A severe phenotype in mice with a duplication of exon 3 in the cystic fibrosis locus. Hum Mol Genet (1993) 1.22
The ovine cathelicidin SMAP29 kills ovine respiratory pathogens in vitro and in an ovine model of pulmonary infection. Antimicrob Agents Chemother (2001) 1.22
Third component of human complement: localization of the internal thiolester bond. Proc Natl Acad Sci U S A (1982) 1.20
Sequence determination of the thiolester site of the fourth component of human complement. Proc Natl Acad Sci U S A (1981) 1.19
Increasing epithelial junction permeability enhances gene transfer to airway epithelia In vivo. Am J Respir Cell Mol Biol (2000) 1.18
The beta-Cys-gamma-Glu thiolester bond in human C3, C4, and alpha 2-macroglobulin. Springer Semin Immunopathol (1983) 1.18
Early-onset inflammatory responses in vivo to adenoviral vectors in the presence or absence of lipopolysaccharide-induced inflammation. Am J Respir Cell Mol Biol (1999) 1.17
Binding of C3b proceeds by a transesterification reaction at the thiolester site. Nature (1982) 1.17
Human coronavirus 229E infects polarized airway epithelia from the apical surface. J Virol (2000) 1.17
Fourth component of human complement: studies of an amine-sensitive site comprised of a thiol component. Biochemistry (1981) 1.17
Primary structure of the fifth component of murine complement. Biochemistry (1987) 1.16
A novel murine beta -defensin expressed in tongue, esophagus, and trachea. J Biol Chem (2000) 1.14
Congeners of SMAP29 kill ovine pathogens and induce ultrastructural damage in bacterial cells. Antimicrob Agents Chemother (2001) 1.14
Effect of glutathione peroxidase activity on lipid peroxidation in biological membranes. Biochim Biophys Acta (1976) 1.12
Infection of human airway epithelia with H1N1, H2N2, and H3N2 influenza A virus strains. Mol Ther (2001) 1.09
Localization of epithelial sodium channel subunit mRNAs in adult rat lung by in situ hybridization. Am J Physiol (1996) 1.09
Susceptibilities of oral bacteria and yeast to mammalian cathelicidins. Antimicrob Agents Chemother (2001) 1.06
NH2-terminal structure and cleavage of guinea pig pro-C3, the precursor of the third complement component. J Biol Chem (1981) 1.05
Phenotypic and genotypic characterizations of Chinese strains of Escherichia coli producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis (1999) 1.05
The superfamily of C3b/C4b-binding proteins. Fed Proc (1987) 1.04
Identification of single amino acids in the human papillomavirus 11 E2 protein critical for the transactivation or replication functions. Virology (1998) 1.02
Structure of murine complement component C3. I. Nucleotide sequence of cloned complementary and genomic DNA coding for the beta chain. J Biol Chem (1984) 1.02
The piglet as a model for B cell and immune system development. Vet Immunol Immunopathol (2008) 1.02
Structure of murine complement component C3. II. Nucleotide sequence of cloned complementary DNA coding for the alpha chain. J Biol Chem (1984) 1.01
cDNA structure of murine C4b-binding protein, a regulatory component of the serum complement system. Biochemistry (1987) 1.01
Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles. J Virol (1993) 1.00
ATPase center of bacteriophage lambda terminase involved in post-cleavage stages of DNA packaging: identification of ATP-interactive amino acids. J Mol Biol (2000) 0.99
In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol Ther (2001) 0.99
Chromosomal location of the genes encoding complement components C5 and factor H in the mouse. J Immunol (1986) 0.97
Development of retroviral vectors for gene transfer to airway epithelia. Curr Opin Mol Ther (2000) 0.96
Diagnosis of pediatric tuberculosis in the modern era. Pediatr Infect Dis J (1999) 0.96
cDNA sequence and tissue distribution of the mRNA for bovine and murine p11, the S100-related light chain of the protein-tyrosine kinase substrate p36 (calpactin I). J Biol Chem (1987) 0.96
The fifth component of complement (C5) in the mouse. Analysis of the molecular basis for deficiency. J Exp Med (1987) 0.96
Isolation and sequence analysis of a cDNA clone encoding the fifth complement component. J Biol Chem (1985) 0.96
Efficient killing of inhaled bacteria in DeltaF508 mice: role of airway surface liquid composition. Am J Physiol (1999) 0.96
The NMR structure of human beta-defensin-2 reveals a novel alpha-helical segment. Biochemistry (2001) 0.95
Mapping of a retinoic acid-responsive element in the promoter region of the complement factor H gene. J Biol Chem (1990) 0.95